Skinvisible (SKVI) Total Non-Current Liabilities (2021 - 2024)
Skinvisible's (SKVI) quarterly Total Non-Current Liabilities came in at $9.4 million in Q4 2024, up 2.09% year-over-year from $9.2 million in Q1 2024, and down 6.49% quarter-over-quarter from $10.0 million in Q3 2024.
Analysis
Skinvisible (SKVI) Total Non-Current Liabilities (2021 - 2024) Analysis & Trends
Skinvisible has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $9.4 million for Q4 2024.
- In Q4 2024, Total Non-Current Liabilities rose 2.09% year-over-year to $9.4 million; the TTM figure through Dec 2024 stood at $9.4 million (up 2.09% YoY), while the FY2024 annual figure was $9.4 million, up 2.09% from the prior year.
- Total Non-Current Liabilities came in at $9.4 million for Q4 2024 at Skinvisible, down from $10.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $10.0 million in Q3 2024 to a low of $5.0 million in Q1 2021.
- Average Total Non-Current Liabilities over 4 years is $7.5 million, with a median of $7.6 million recorded in 2022.
- Year-over-year, Total Non-Current Liabilities jumped 44.2% in 2023 and increased 2.09% in 2024.
- Over 4 years, Total Non-Current Liabilities stood at $5.6 million in 2021, then grew by 22.8% to $6.9 million in 2022, then soared by 33.37% to $9.2 million in 2023, then gained by 2.09% to $9.4 million in 2024.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $9.4 million in Q4 2024, $10.0 million in Q3 2024, and $9.7 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.03 Bn | 625.27 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 441.56 Bn | 434.99 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 364.45 Bn | 357.31 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 267.46 Bn | 259.77 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 158.77 Bn | 147.08 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 44.15 Bn | 44.15 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.31 Bn | 20.77 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.29 Bn | 18.63 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 9.36 Mn |
| Sep 30, 2024 | 10.01 Mn |
| Jun 30, 2024 | 9.73 Mn |
| Mar 31, 2024 | 9.45 Mn |
| Dec 31, 2023 | 9.17 Mn |
| Sep 30, 2023 | 8.89 Mn |
| Jun 30, 2023 | 8.62 Mn |
| Mar 31, 2023 | 8.34 Mn |
| Dec 31, 2022 | 6.87 Mn |
| Sep 30, 2022 | 6.50 Mn |
| Jun 30, 2022 | 6.12 Mn |
| Mar 31, 2022 | 5.79 Mn |
| Dec 31, 2021 | 5.60 Mn |
| Sep 30, 2021 | 5.41 Mn |
| Jun 30, 2021 | 5.15 Mn |
| Mar 31, 2021 | 5.02 Mn |